In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model
Fig 5
Partial Rank Correlation Coefficient (PRCC) scatterplots of indicative model parameters and tumor proliferation features.
All model parameters are varied simultaneously. The ordinate represents the sum of cisplatin and gemcitabine cell kill rates. The sample has a size of N = 553. It originates from a Latin Hypercube Sampling run of 8000 combinations of parameter values after excluding the ones with negative growth rates, Td below 26 days and stem cell fractions higher than 1‰. The PRCC value and the corresponding p-value are displayed in each plot. The scatterplots are displayed for the following model parameters and proliferation features: (A) duration of cell cycle of LIMP cells, (B) number of stem and LIMP cells that enter the apoptotic pathway per hour, (C) fraction of stem cells that undergo symmetric division, (D) fraction of newborn cells that enter a quiescent state following mitosis, (E) proportion of living tumor cells that are actively proliferating and (F) doubling time of tumor volume. Abbreviations: cis-DDP: cisplatin, dFdC: gemcitabine, LIMP: LImited Mitotic Potential tumor cell (also called committed or restricted progenitor cell), G0: dormant, resting phase.